EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Zewen Wu, Po-Cheng Shih, Shiow-Ing Wang, Gema Hernández Ibarburu, Qing-Wen Wang, James Cheng Chung Wei, Liyun Zhang

CHEST · 2026-02 · 169 (2) · 428-439

DOI: 10.1016/j.chest.2025.09.009 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CHEST, 2026-02. Verfasst von Zewen Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Rheumatoid, Lung Diseases, Interstitial, Rituximab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) confers an increased risk of mortality among patients with RA. However, the optimal treatment strategies remain uncertain due to the limited high-quality evidence available. RESEARCH QUESTION: In patients with RA-ILD, how does tocilizumab compare with rituximab in terms of prognosis? STUDY DESIGN AND METHODS: This study used the TriNetX US Collaborative Network database to emulate a target trial of patients with RA-ILD treated with either tocilizumab or rituximab. Propensity score matching was used to balance disease severity between groups. Primary and secondary outcomes included all-cause mortality and medical utilizations risk. Hazard ratios (HRs) were estimated by using Cox regression. Subgroup and sensitivity analyses were performed. RESULTS: Each matched cohort included 1,194 patients. Over 5 years, all-cause mortality did not differ significantly between the tocilizumab and rituximab groups (HR, 1.073; 95% CI: 0.881-1.305). Secondary outcomes, including hospitalization and mechanical ventilation, were also comparable. Excluding patients with other systemic autoimmune rheumatic disease-related interstitial lung diseases yielded consistent results. In sensitivity analysis, patients with RA-ILD with elevated baseline inflammatory markers experienced higher risks with tocilizumab in mechanical ventilation (HR, 1.936; 95% CI, 1.125-3.331) and all-cause mortality (HR, 1.403; 95% CI: 1.013-1.942). In addition, patients naive to tumor necrosis factor inhibitor therapy with high inflammatory markers had an increased risk of mechanical ventilation (HR, 1.539; 95% CI, 1.074-2.206). INTERPRETATION: In this real-world cohort, tocilizumab and rituximab displayed comparable effectiveness and safety in RA-ILD. However, among patients with elevated baseline inflammatory markers, rituximab might be a safer choice than tocilizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthritis, RheumatoidLung Diseases, InterstitialRituximabAntirheumatic AgentsHumansFemaleMaleMiddle AgedAgedTreatment OutcomePropensity ScoreUnited States

Stichwörter der Autor:innen

interstitial lung diseasemedical utilizationmortalityrheumatoid arthritisrituximabtocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedRituximabAntirheumatic Agents

Autor:innen und Institutionen

  • Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • TriNetX, Cambridge, MA.
  • Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; Shenzhen Key Laboratory of Inflammatory and Immunology Diseases (Q.-W. W.), Shenzhen, Guangdong, China.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Office of Research and Development, Asia University, Taichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichun…

Zitieren

APA

Wu, Z., Shih, P. C., Wang, S. I., Ibarburu, G. H., Wang, Q. W., Wei, J. C. C., & Zhang, L. (2026). Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease. CHEST, 169(2), 428-439. https://doi.org/10.1016/j.chest.2025.09.009

Vancouver

Wu Z, Shih PC, Wang SI, Ibarburu GH, Wang QW, Wei JCC, et al. Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease. CHEST. 2026;169(2):428-439. doi:10.1016/j.chest.2025.09.009

BibTeX
@article{Wu2026,
  author = {Wu, Zewen and Shih, Po-Cheng and Wang, Shiow-Ing and Ibarburu, Gema Hernández and Wang, Qing-Wen and Wei, James Cheng Chung and Zhang, Liyun},
  title = {Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease},
  journal = {CHEST},
  year = {2026},
  volume = {169},
  number = {2},
  pages = {428--439},
  doi = {10.1016/j.chest.2025.09.009}
}
Kostenlos starten →